Policosanol: Benefits, Dosage, Forms & Research

What the Research Says

Policosanol presents one of the most controversial evidence bases in supplement research. Numerous Cuban studies (Mas et al., 1999; Gouni-Berthold & Berthold, 2002) reported LDL reductions of 20-30%, but independent replication attempts have largely failed. Berthold et al. (2006) conducted a rigorous German RCT (n=143) using Cuban-sourced policosanol and found no significant effect on any lipid parameter, directly contradicting the Cuban findings. Greyling et al. (2006) in South Africa similarly found no cholesterol-lowering effect. The Cochrane Database notes that almost all positive studies originate from a single Cuban research group, raising concerns about publication bias or methodological issues. Policosanol remains safe but its efficacy for cholesterol management is not reliably established.

Benefits of Policosanol

• LDL reduction (Cuban data) — Mas et al. (1999) reported LDL cholesterol reductions of 24% with 10mg policosanol daily and 30% at 20mg in multiple Cuban studies, though these results have been questioned.
• Anti-platelet activity — Arruzazabala et al. (1997) demonstrated that policosanol inhibits platelet aggregation in both in vitro and clinical studies, potentially through thromboxane/prostacyclin modulation.
• Antioxidant effects — policosanol has shown modest antioxidant capacity in preclinical studies, potentially reducing LDL oxidation, though clinical significance is uncertain.
• Safety profile — across all studies (Cuban and independent), policosanol consistently demonstrates excellent tolerability with very few adverse effects, making it among the safest supplements tested.

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

• Very few side effects reported across all studies
• Mild weight loss (occasionally noted)
• Mild GI symptoms (rare)
• Skin rash (very rare)

Drug & Supplement Interactions

• Anticoagulants/antiplatelets — additive anti-platelet effects may increase bleeding risk
• Statins — theoretical additive cholesterol-lowering; no adverse interactions reported
• Levodopa — one case report of interaction; caution in Parkinson's patients